Biomaterial Database

[Maximal androgen blockade in metastatic prostatic carcinoma]. 1997

T Jørgensen, and K J Tveter

Urologisk avdeling Kirurgisk klinikk, Ullevål sykehus, Oslo.

In Norway the standard treatment for metastatic prostatic cancer has been surgical or medical castration. Only recently have antiandrogens been approved for treatment of advanced cancer of the prostate. The authors examine the principles for total or maximal androgen blockade and discuss American and European studies that indicate an improvement in survival as a result of maximal androgen blockade therapy in patients with low volume disease and good performance. Though not yet statistically proven in prospective trials, it is recommended that such patients should be given maximal androgen blockade therapy, also in Norway.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D011471	Prostatic Neoplasms	Tumors or cancer of the PROSTATE.	Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000726	Androgen Antagonists	Compounds which inhibit or antagonize the biosynthesis or actions of androgens.	Androgen Antagonist,Antiandrogen,Antiandrogens,Anti-Androgen Effect,Anti-Androgen Effects,Antiandrogen Effect,Antiandrogen Effects,Antagonist, Androgen,Antagonists, Androgen,Anti Androgen Effect,Anti Androgen Effects,Effect, Anti-Androgen,Effect, Antiandrogen,Effects, Anti-Androgen,Effects, Antiandrogen